Fred Lawrence Ciske
21Patents
4h-index
41Co-inventors
63Inventor score
Filing activity: Apr 18, 1997 → Jun 9, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6624159B2 | Heterocycle carboxamides as antiviral agents | Human Necessities | 17 | Expired |
| US6559145B2 | Heterocycle carboxamides as antiviral agents | Chemistry; Metallurgy | 15 | Expired |
| US9180116B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 6 | Active |
| US9440919B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | Human Necessities | 4 | Active |
| US9487478B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 4 | Active |
| US6365612B2 | Benzosultam oxazolidinone antibacterial agents | Human Necessities | 2 | Expired |
| US9701630B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | Human Necessities | 2 | Active |
| US6004959A | Alkyloxyamino substituted fluorenones and their use as protein kinase-C inhibitors | Chemistry; Metallurgy | 2 | Expired |
| US8536185B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | Chemistry; Metallurgy | 1 | Active |
| US9688627B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Chemistry; Metallurgy | 0 | Active |
| US11066361B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US6831081B2 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | Human Necessities | 0 | Expired |
| US6903097B2 | Heterocycle carboxamides as antiviral agents | Chemistry; Metallurgy | 0 | Expired |
| US9676712B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Chemistry; Metallurgy | 0 | Active |
| US10729810B2 | Methods, systems, and compositions for promoting bone growth | Human Necessities | 0 | Active |
| US11884624B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US6825225B2 | Bicyclic isoxazolinones as antibacterial agents | Human Necessities | 0 | Expired |
| US10556862B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US9126973B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | Chemistry; Metallurgy | 0 | Active |
| US8450326B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | General | 0 | Revoked |
| US9120820B2 | Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteins | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.